Chemed

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemed exceeds earnings expectations, focuses on strategic growth initiatives

Chemed's strong financial performance in 2022 was supported by targeted hiring and retention efforts.
Both VITAS and Roto-Rooter are focusing on improving staffing and revenue growth.
Chemed's strategic initiatives position the company well for future growth and operational efficiency.
The company's emphasis on culture and strategic approaches enhances valuation in the M&A market.

Chemed reports strong Q1 performance, optimistic about growth trajectory

Chemed's Q1 2023 earnings call highlighted a positive performance trajectory post-pandemic, with a focus on VITAS' growth and operational strategies. The company addressed challenges related to Medicare reimbursement rates and emphasized opportunities for further expansion and staff satisfaction.

Chemed's VITAS shines, Roto-Rooter adapts to consumer challenges

Chemed's Q2 2023 earnings call highlighted VITAS' strong performance and operational improvements post-pandemic.
Roto-Rooter faced challenges in consumer spending but focused on enhancing online presence and conversion rates.
Both segments showcased resilience amidst economic headwinds, with strategic initiatives in place to drive growth and operational efficiency.
Chemed's strategic cost management and revenue generation strategies position the company for sustainable growth and margin protection.

Chemed reports strong Q3 performance, eyes growth amid economic challenges

Chemed's diversified business segments showed resilience and growth potential, with VITAS Healthcare and Roto-Rooter both demonstrating strengths and addressing challenges. The company remains cautiously optimistic about 2024, focusing on operational efficiency and market dynamics for sustained performance.

Chemed's VITAS shines in Q4 with strong growth, Roto-Rooter faces challenges

Chemed's VITAS segment excelled with strong revenue growth and operational improvements, while Roto-Rooter faced challenges in call volume.
Management's confidence in sustained growth and margin improvement presents opportunities for both VITAS and Roto-Rooter in 2024.
Strategies to address challenges and capitalize on opportunities will be crucial for Chemed's divisions to meet their forecasted targets.
Overall, Chemed's performance in Q4 2023 sets a positive tone for the company's outlook and strategic initiatives moving forward.

Chemed excels in hospice segment, Roto-Rooter faces commercial challenges

Chemed's VITAS segment outperformed, while Roto-Rooter faced challenges, prompting strategic actions to enhance commercial performance and drive growth.

Chemed's VITAS shines in Q2 2024, Roto-Rooter faces revenue challenges

Chemed's VITAS segment is driving revenue growth and margin expansion, while Roto-Rooter faces challenges in revenue decline. The company aims to capitalize on growth opportunities in the hospice services sector.

Chemed's VITAS shines amid Roto-Rooter's challenges in Q3 2024

Chemed's earnings call showcased VITAS' resilience and growth prospects, while addressing Roto-Rooter's challenges and strategic adjustments. The company remains optimistic about adjusted net income outlook for the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arbor Realty Trust

Bio-Rad Laboratories

Cathay General Bancorp

Materialise NV

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like CATY, BIO, CHE, MTLS and ABR.

5 Stocks to Buy as Analysts Initiate Coverage

Cogent Communications Holdings

Carlisle Companies

Dover

Fidelity National Financial

Federal Realty Investment Trust

Illinois Tool Works

KLA-Tencor

Quaker Chemical

Microchip Technology

NewMarket

Terreno Realty

Willis Towers

This weekly article series provides a summary of dividend changes. A summary table presents relevant data and key statistics of dividend increases.

Dividend Increases: July 31-August 6, 2021

Chemed Corporation (CHE) CEO Kevin McNamara on Q2 2021 Results - Earnings Call Transcript

Chemed (CHE) reports better-than-expected earnings and revenues with strong Roto-Rooter segment performance driving the top line in second-quarter 2021.

Chemed (CHE) Q2 Earnings & Revenues Top Estimates, Margins Up

Chemed (CHE) delivered earnings and revenue surprises of 3.37% and 0.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Q2 Earnings and Revenues Surpass Estimates

Shares of Chemed (NYSE:CHE) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 4.31% over the past year to $4.60, which beat the estimate of $4.29.

Chemed: Q2 Earnings Insights

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation Second-Quarter 2021 Earnings

Chemed Reports Second-Quarter 2021 Results - Full-Year 2021 Guidance Increased

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemed (CHE) Earnings Expected to Grow: Should You Buy?

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the second quarter ended June 30, 2021, on Tuesday, July 27, 2021, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, July 28, 2021, to discuss the company's quarterly results and to provide an update on its business. The toll-free dial-in number for the conference call is 844-743-2500 for U

Chemed To Report Second-Quarter 2021 Earnings July 27, Related Conference Call To Be Held On July 28

Chemed (CHE) reported earnings 30 days ago. What's next for the stock?

Why Is Chemed (CHE) Up 4.7% Since Last Earnings Report?

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021, at approximately 11:30 a.m. (ET). The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 d

Chemed Corporation to Present at the Jefferies 2021 Virtual Healthcare Conference

DaVita

U.S. Physical Therapy

3 Stocks to Bank on Rebounding Outpatient Home Health Industry

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at approximately 10:20 a.m. (ET). The audio webcast can be accessed by visiting the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours after the live presentation and will be accessible for 90 days. Listed on the New York Stock Exchange an

Chemed Corporation to Present at the 2021 RBC Capital Markets Global Healthcare Conference

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021, at 12:30 PM (ET). The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days. Listed on the New Yor

Chemed Corporation to Present at the BofA Securities 2021 Virtual Health Care Conference

Chemed's (CHE) CEO Kevin McNamara on Q1 2021 Results - Earnings Call Transcript

Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.

Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up

Chemed (CHE) delivered earnings and revenue surprises of 5.71% and 2.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Q1 Earnings and Revenues Beat Estimates

Shares of Chemed (NYSE:CHE) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 20.65% over the past year to $4.44, which beat the estimate of $4.02.

Chemed: Q1 Earnings Insights

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation First-Quarter 2021 Earnings Results

Chemed Reports First-Quarter 2021 Results

On Tuesday, April 27, Chemed (NYSE:CHE) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Earnings Outlook for Chemed

The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.

VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation to report first-quarter 2021 Earnings April 27, Related conference call on April 28

Chemed To Report First-Quarter 2021 Earnings April 27, Related Conference Call To Be Held On April 28

Emergent BioSolutions

ICON

Select Medical Holdings

The following health care companies have grown their earnings per share over a five-year period. According to the GuruFocus discounted cash flow calculator as of March 31, all of them also trade with a margin of safety.

5 Health Care Stocks Boosting Earnings

Chemed Corporation (CHE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

News for Chemed Stock (CHE)